

Virtual Journal club



Elena Izmailova CSO **Koneksa Health**

When Work Hits Home: The Cancer-Treatment Journey of a Clinical Scientist Driving Digital Medicine

January 10th, 2023 12pm ET



But first, housekeeping

- Please note today's session is being recorded
- To ask a question for discussion during Q&A, please:
 - Either 'raise your hand' in the participant window and moderator will unmute you to ask your question live, or
 - Type your question into the chat box
- Slides and recording will be available after today's session

Digital Health Technologies in Cancer Diffe


Application	Concept	Measurement examples	ePRO	BioMeT	Maturity
Diagnosis	Multidomain tool to diagnose complex medical conditions that require longitudinal surveillance, eg, frailty syndromes	Activities of daily living	+		
-		% time in a bed or chair		+	
		Timed up and go		+	
		Grip strength		+	
Prognosis or risk	Determination of near-term risk for adverse health outcomes including treatment toxicity	Physical function	+		
		Physiologic measure composites (eg, VO2max [est])		+	
		Free living gait speed		+	
Treatment efficacy	Assessment of physiologic response or patient-reported improvement from treatment	Quality of life	+		
		Physiologic measure composites (eg, VO2max [est])		+	
		Physical activity		+	
		Other fitness measures (eg, heart rate variability)		+	
Adverse effect monitoring	Evaluation of treatment-related toxicities	Adverse event self-report	+		
		Vital sign monitoring		+	
		Physical activity		+	

🖌 koneksa

Izmailova ES, Wood WA.JCO Clin Cancer Inform. 2021 Jun;5:728-733. doi: 10.1200/CCI.21.00019.



Patient Journey





Source: ES Izmailova, RD Ellis JCO Clinical Cancer Informatics 6, e2200033

Digital Monitoring Is Useful




Mini–Review 🔂 Open Access 💿 🕢 😒

Remote Digital Monitoring for Medical Product Development

Elena S. Izmailova, John A. Wagner, Nadir Ammour, Ninad Amondikar, Andrea Bell-Vlasov, Steven Berman, Dan Bloomfield, Linda S. Brady, Xuemei Cai, Roberto A. Calle, Michelle Campbell, Francesca Cerreta, Ieuan Clay, Luca Foschini, Pat Furlong, Rob Goldel, Jennifer S. Goldsack, Peter M.A. Groenen, Amos Folarin, Jill Heemskerk, Peter Honig, Matthew Hotopf, Tania Kamphaus, Daniel R. Karlin, Christopher Leptak, Qi Liu, Husseini Manji, Robert J. Mather, Joseph P. Menetski, Vaibhav A. Narayan, Elektra Papadopoulos, Bakul Patel, Bray Patrick-Lake, Jagdeep T. Podichetty, Abhishek Pratap, Laurent Servais, Diane Stephenson, Pam Tenaerts, Bruce J. Tromberg, Steve Usdin, Srikanth Vasudevan, Vadim Zipunnikov, Steven C. Hoffmann 🗙 ... See fewer authors 🔿

First published: 23 July 2020 | https://doi.org/10.1111/cts.12851 | Citations: 10

- Virtual care made significant inroads during the pandemic, and it works!
- DHT derived data can help virtual care delivery, provide useful information and minimize hospital stay



Insights

- Virtual vital sign monitoring
- Physical activity monitoring

Digital Biomarkers Viewpoint - Review Article

Digit Biomark 2021;5:103–113 DOI: 10.1159/000515110 Received: October 21, 2020 Accepted: December 28, 2020 Published online: April 22, 2021

Remote Cardiac Safety Monitoring through the Lens of the FDA Biomarker Qualification Evidentiary Criteria Framework: A Case Study Analysis

Elena S. Izmailova^a William A. Wood^b Qi Liu^c Vadim Zipunnikov^d Daniel Bloomfield^e Jason Homsy^f Steven C. Hoffmann^g John A. Wagner^h Joseph P. Menetski^g

*Koneksa Health, New York, NY, USA, ^bLineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC, USA; ^cOffice of Clinical Pharmacology, Office of Translational Sciences, Center for Drug Evaluation and Research Food and Drug Administration, Silver Spring, MD, USA; ^dJohns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA; ^eAnthos Therapeutics, Cambridge, MA, USA; ^tTakeda Pharmaceuticals International, Cambridge, MA, USA; ^oFoundation for the National Institutes of Health (NIH), North Bethesda, MD, USA; ^hCygnal Therapeutics, Cambridge, MA, USA

"Inactive" patients:

- ↑ hospitalizations during RT 50% v. 9%, p=0.004
- ↓ rate of completing RT without delay >1 week 67% v. 97%, p=0.006

• ↓ PFS median 5.3 months v. 18.3 months, HR=4.52, p<0.001

• ↓ OS

median 15.0 months v. not reached, HR=3.88, p=0.007

20000 00 Performance Status 0 "Verv Active" × 18000 Ó Performance Status 1 D Performance Status 2 16000 14000 12000 10000 8000 6000 4000 2000 30 R

Int J Radiation Oncol Biol Phys, Vol. 105, No. 4, pp. 745e751, 2019

36% reduction in the risk of hospitalization for every 1,000 steps taken each day (HR=0.64, p<0.001)




K koneksa

Data Sharing Is Important!



JCO[®] Clinical Cancer Informatics



Date



An American Society of Clinical Oncology Journal

DHE

Izmailova ES, Ellis RD.JCO Clin Cancer Inform. 2022 Sep;6:e2200033. doi: 10.1200/CCI.22.00033.

Final words

Data sharing is important!

JCO[®] Clinical Cancer Informatics

and downs, but my digital technologies were my North Star. I'm very grateful to my family, friends, and colleagues who supported me through this journey (and looked at my results too!), and the team of outstanding physicians and nurses (receptive to my data gathering and sharing too!) who got me to where I am now, so I can continue to live and work. I am also grateful to the fact that I live in a time when early cancer detection is widespread and readily available, making cancer a curable condition for many patients.

Some days were better than others; I had my ups



Acknowledgments

Thanks to colleagues across

> .com .edu

> > and

.org

In particular

- o Chris Benko, Koneksa Health
- o Adam Dicker, Jefferson Center for Digital Health
- o Robert Ellis, Koneksa Health
- o Nitin Ohri, Montefiore Medical Center
- o Andrew Pearlmutter, Koneksa Health
- o Diane Stephenson, C-Path Institute
- o John Wagner, Koneksa Health
- William Wood, Lindenberg Cancer Center, UNC





Join us at our upcoming DiMe webinar!



Join us on Wednesday, February 1st at 11:00-12:00 ET for our next webinar: Increasing software innovation in digital health products through unified cross architecture programming

Hear from thought leaders at **Intel**, **Canon Medical**, and **Oracle** as they discuss how digital health product teams can deliver groundbreaking solutions that are both innovative and equitable.





Ashveena Gajeelee Founder and CEO Veritas Consortium, LLC

Applicability of Artificial Intelligence in Healthcare in Resource-Poor Settings

Thursday, February 9th, 2023 12pm ET



Mansa Shroff Director of Business Development, Chief of Staff WKD.SMRT

THANK YOU

Sarah Sheehan <u>Sarah.Sheehan@dimesociety.org</u>

Linette Demers Linette@dimesociety.org





linkedin.com/company/dime-society

